RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Age, genes and response to Parkinson's treatment

Researchers are studying how age at onset and genetic differences relate to progression and treatment outcomes.

Learning by observing or collecting information · Study reference: DRKS00028134

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported date)
2022-01-20

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 18 years to 99 years · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion criteria: Parkinson's disease Exclusion criteria: age <18 years
Full study name & original research details

Official study title

AGe-PD: Influence of Age and Genetic Status on the Progression and Treatment Response of Parkinson’s Disease - AGe-PD

Short title used by the registry

AGe-PD: Influence of Age and Genetic Status on the Progression and Treatment Response of Parkinson’s Disease

Original description

Intervention: Group 1: Parkinson’s patients with deep brain stimulation (DBS) and a young age at onset (45 years) Primary outcome: data of clinical routine: evaluation appointment, operation protocol, appointments after 3 and 12 month after the surgery. further annual follow up. Data used in the registry are clinical scores (UPDRS, BDI, QUIP, Strakstein-Apathie-Skala, DemTect, MMST, PDQ39), pre and postoperative videoducumentation, comorbidities, labresults, Levodopaequiveleny dosage, cerebral MRI and CT, localization date of the electrodes, adverse events and severe adverse events, side effects of the stimulation, settings of deep brain stimulation (chosen contacts, impedance, amplitude, pulse width, frequence) from the clinical routine. Secondary outcome: Differentiation of patients with respect to the study's primary endpoints based on age at disease onset, genotype or phenotype, and response to deep brain stimulation (DBS).

Conditions reported: G20;Parkinson disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Observational
Interventions
Group 1: Parkinson’s patients with deep brain stimulation (DBS) and a young age at onset (45 years)
Phases
Not reported
Sponsor
Charité Campus Charité Mitte
Start date reported by registry
2022-01-20 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-14 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Patricia Krause · 030450660454 · patricia.krause@charite.de

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Germany

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.